viewValiRx PLC

Yorkville converts loan notes into ValiRx shares

The notes were converted at 5.625p a share, versus a current share price of 5.15p..

Cancer cells
The cancer treatment developer is poised for a busy year ahead

Finance house Yorkville has elected to convert a further portion of tranche 1 of the convertible loan facility it provides to ValiRx Plc (LON:VAL).

Yorkville converted US$150,000 of tranche 1 convertible loan notes, plus accrued interest of US$15,840, into 2.39mln shares at a conversion price of 5.625p per share.

Shares of the cancer treatments developer currently trade at around 5.15p, having fallen from 5.37p on news of the conversion.

Quick facts: ValiRx PLC

Price: 6.75 GBX

Market: AIM
Market Cap: £2.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio. Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship...

on 19/7/18

2 min read